# US 6,682,736 B1 · Human monoclonal antibodies to CTLA-4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,682,736 B1
- Document ID: US6682736B1
- Status: Granted
- Kind: B1
- Application number: 09/472,087
- Filed: 1999-12-23
- Granted: 2004-01-27
- Earliest claimed: 1998-12-23
- Assignees: Abgenix, Inc.; Pfizer Inc.
- Inventors: Douglas Charles Hanson; Mark Joseph Neveu; Eileen Elliott Mueller; Jeffrey Herbert Hanke; Steven Christopher Gilman; C. Geoffrey Davis; Jose Ramon Corvalan
- Web page: https://patentgrep.com/patent/US6682736B1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 2317/21: from primates, e.g. man
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

## Claims

### Claim 1

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, comprising a heavy chain variable region amino acid sequence that comprises a contiguous amino acid sequence from within an FR1 sequence through an FR3 sequence that utilizes a human VH3-33 family gene and that comprises at least one of the amino acid substitutions in any one of SEQ ID NO: 74-79 and 81-84 as compared to SEQ ID NO: 72.

### Claim 2 (depends on 1)

The monoclonal antibody or antigen-binding portion thereof of claim 1, wherein the heavy chain variable region amino acid sequence comprises amino acid residues 1-89 of SEQ ID NO: 9.

### Claim 3 (depends on 2)

The monoclonal antibody or antigen-binding portion thereof of claim 2, further comprising a light chain variable region amino acid sequence that comprises the variable region of SEQ ID NO: 22.

### Claim 4

An isolated human monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, wherein the antibody or antigen-binding portion thereof has a binding affinity that is about 10−9 M, or greater affinity; possesses a selectivity for CTLA-4 over CD28, B7-2, CD44, and hIgG1 of greater than about 100:1; inhibits binding between CTLA-4 and B7-2 with an IC50 of lower than about 100 nM; and inhibits binding between CTLA-4 and B7-1 with an IC50 of lower than about 100 nM.

### Claim 5 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof competes for binding with CTLA-4 with an antibody comprising a heavy chain amino acid sequence comprising amino acid residues 1-89 of SEQ ID NO: 9 and a light chain amino acid sequence comprising SEQ ID NO: 22.

### Claim 6

An isolated human monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, wherein the antibody or antigen-binding portion thereof has a binding affinity that is about 10−9 M, or greater affinity; possesses a selectivity for CTLA-4 over CD28, B7-2, CD44, and hIgG1 of greater than about 100:1; inhibits binding between CTLA-4 and B7-2 with an IC50 of lower than about 100 nM; and inhibits binding between CTLA-4 and B7-1 with an IC50 of lower than about 100 nM; and cross competes for binding with CTLA-4 with an antibody comprising a heavy chain amino acid sequence comprising amino acid residues 1-89 of SEQ ID NO: 9 and a light chain amino acid sequence comprising SEQ ID NO: 22.

### Claim 7 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof is not cross reactive with CTLA-4 from lower mammalian species.

### Claim 8 (depends on 7)

The monoclonal antibody or antigen-binding portion thereof of claim 7, wherein the lower mammalian species comprises mouse, rat, and rabbit.

### Claim 9 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof is cross reactive with CTLA-4 from primates.

### Claim 10 (depends on 9)

The monoclonal antibody or antigen-binding portion thereof of claim 9, wherein the primates comprise cynomolgous and rhesus monkeys.

### Claim 11 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the selectivity is about 500:1 or greater.

### Claim 12 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the binding affinity of the monoclonal antibody or antigen-binding portion thereof is about 10−10 M, or greater affinity.

### Claim 13 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof inhibits binding between CTLA-4 and B7-2 with an IC50 of lower than about 0.38 nM.

### Claim 14 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof inhibits binding between CTLA-4 and B7-1 with an IC50 of lower than about 0.50 nM.

### Claim 15 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof enhances IL-2 production in a T cell blast/Raji assay by about 500 pg/ml or greater.

### Claim 16 (depends on 15)

The monoclonal antibody or antigen-binding portion thereof of claim 15, wherein the monoclonal antibody or antigen-binding portion thereof enhances IL-2 production in a T cell blast/Raji assay by about 3846 pg/ml or greater.

### Claim 17 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof enhances IFN-γ production in a T cell blast/Raji assay by about 500 pg/ml or greater.

### Claim 18 (depends on 17)

The monoclonal antibody or antigen-binding portion thereof of claim 17, wherein the monoclonal antibody or antigen-binding portion thereof enhances IFN-γ production in a T cell blast/Raji assay by about 1233 pg/ml or greater.

### Claim 19 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof induces IL-2 production in a hPBMC or whole blood superantigen assay by about 500 pg/ml or greater.

### Claim 20 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof induces IL-2 production in a hPBMC or whole blood superantigen assay by about 1500 pg/m1 or greater.

### Claim 21 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof induces IL-2 production in a hPBMC or whole blood superantigen assay by greater than about 30% relative to control.

### Claim 22 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof induces IL-2 production in a hPBMC or whole blood superantigen assay by greater than about 50% relative to control.

### Claim 23

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, comprising a heavy chain amino acid sequence comprising human FR1, FR2, and FR3 sequences that utilize a human VH 3-33 gene family operably linked in frame with a CDR1, a CDR2, and a CDR3 sequence, the CDR1 sequence being independently selected from amino acid residues 17-26 of SEQ ID NO: 72, 73, 74, 75, 76, 9, 81 or 83, amino acid residues 13-22 of SEQ ID NO: 77 or 78, amino acid residues 18-27 of SEQ ID NO: 79, amino acid residues 16-25 of SEQ ID NO: 82, or amino acid residues 15-24 of SEQ ID NO: 84; the CDR2 sequence being independently selected from amino acid residues 41-55 of SEQ ID NO: 72, 73, 74, 75, 76, 9, 81 or 83, amino acid residues 37-51 of SEQ ID NO: 77 or 78, amino acid residues 42-56 of SEQ ID NO: 79, amino acid residues 40-54 of SEQ ID NO: 82, or amino acid residues 39-53 of SEQ ID NO: 84; and the CDR3 sequence being independently selected from amino acid residues 90-100 of SEQ ID NO: 73 or 81, amino acid residues 90-98 of SEQ ID NO: 74 or 76, amino acid residues 90-99 of SEQ ID NO: 75, amino acid residues 86-94 of SEQ ID NO: 77 or 78, amino acid residues 91-99 of SEQ ID NO: 79, amino acid residues 89-99 of SEQ ID NO: 82, amino acid residues 90-104 of SEQ ID NO: 83, or amino acid residues 88-99 of SEQ ID NO: 84.

### Claim 24

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, comprising a heavy chain amino acid sequence comprising human FR1, FR2, and FR3 sequences that utilize a human VH 3-33 gene family operably linked in frame with a CDR1, a CDR2, and a CDR3 sequence, which antibody or antigen-binding portion thereof has the following properties:
a binding affinity for CTLA-4 that is about 10−9 M, or greater affinity;
inhibits binding between CTLA-4 and B7-1 with an IC50 of about 100 nM or lower;
inhibits binding between CTLA-4 and B7-2 with an IC50 of about 100 nM or lower; and
enhances cytokine production in a human T cell blast/Raji assay by 500 pg/ml or greater.

### Claim 25

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, comprising a heavy chain amino acid sequence comprising FR1, PR2, and FR3 sequences operably linked in frame with a CDR1, a CDR2, and a CDR3 sequence, the CDR1 sequence being independently selected from amino acid residues 17-26 of SEQ ID NO: 72, 73, 74, 75, 76, 9, 81 or 83, amino acid residues 13-22 of SEQ ID NO: 77 or 78, amino acid residues 18-27 of SEQ ID NO: 79, amino acid residues 16-25 of SEQ ID NO: 82, amino acid residues 15-24 of SEQ ID NO: 84, or amino acid residues 24-31 of SEQ ID NO: 86; the CDR2 sequence being independently selected from amino acid residues 41-55 of SEQ ID NO: 72, 73, 74, 75, 76, 9, 81 or 83, amino acid residues 37-51 of SEQ ID NO: 77 or 78, amino acid residues 42-56 of SEQ ID NO: 79, amino acid residues 40-54 of SEQ ID NO: 82, amino acid residues 39-53 of SEQ ID NO: 84, or amino acid residues 44-61 of SEQ ID NO: 86; and the CDR3 sequence being independently selected from amino acid residues 90-100 of SEQ ID NO: 73 or 81, amino acid residues 90-98 of SEQ ID NO: 74 or 76, amino acid residues 90-99 of SEQ ID NO: 75, amino acid residues 86-94 of SEQ ID NO: 77 or 78, amino acid residues 91-99 of SEQ ID NO: 79, amino acid residues 89-99 of SEQ ID NO: 82, amino acid residues 90-104 of SEQ ID NO: 83, amino acid residues 88-99 of SEQ ID NO: 84, or amino acid residues 94-102 of SEQ ID NO: 86,
which antibody or antigen-binding portion thereof has the following properties:
a binding affinity for CTLA-4 that is about 10−9 M, or greater affinity;
inhibits binding between CTLA-4 and B7-1 with an IC50 of about 100 nM or lower;
inhibits binding between CTLA-4 and B7-2 with an IC50 of about 100 nM or lower; and
enhances cytokine production in a human T cell blast/Raji assay by 500 pg/ml or greater.

### Claim 26

A monoclonal antibody or antigen-binding portion thereof that specifically binds CTLA-4, having a light chain CDR1 sequence, CDR2 sequence and CDR3 sequence, comprising amino acid residues 17-27, 43-49 and 82-90 of SEQ ID NO: 96.

### Claim 27 (depends on 26)

The monoclonal antibody or antigen-binding portion thereof of claim 26 comprising the light chain variable region amino acid sequence in SEQ ID NO: 22.

### Claim 28 (depends on 26)

The monoclonal antibody or antigen-binding portion thereof of claim 26 comprising a light chain amino acid sequence comprising SEQ ID NO: 22.

### Claim 29 (depends on 26)

The monoclonal antibody or antigen-binding portion thereof according to claim 26, comprising amino acid residues 17-90 of SEQ ID NO: 96.

### Claim 30

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, comprising a heavy chain amino acid sequence comprising amino acid residues 1-89 of SEQ ID NO: 9 and a light chain amino acid sequence comprising SEQ ID NO: 22.

### Claim 31

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, having a heavy chain CDR1 sequence, CDR2 sequence and CDR3 sequence, comprising amino acid residues 17-26, 41-55 and 90-105 of SEQ ID NO: 80.

### Claim 32 (depends on 31)

The monoclonal antibody or antigen-binding portion thereof according to claim 31, further comprising a light chain CDR1 sequence, CDR2 sequence and CDR3 sequence, comprising amino acid residues 17-27, 43-49 and 82-90 of SEQ ID NO: 96.

### Claim 33 (depends on 32)

The monoclonal antibody or antigen-binding portion thereof according to claim 32, comprising amino acid residues 17-105 of SEQ ID NO: 80 and amino acid residues 17-90 of SEQ ID NO: 96.

### Claim 34 (depends on 31)

The monoclonal antibody or antigen-binding portion thereof of claim 31 comprising a heavy chain variable region amino acid sequence that comprises the variable region amino acid sequence in SEQ ID NO: 70.

### Claim 35 (depends on 34)

The monoclonal antibody or antigen-binding portion thereof of claim 34, further comprising a light chain variable region amino acid sequence that comprises the variable region amino acid sequence in SEQ ID NO: 71.

### Claim 36

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4 comprising a light chain amino acid sequence comprising SEQ ID NO: 71.

### Claim 37

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4 comprising a heavy chain amino acid sequence comprising SEQ ID NO: 70.

### Claim 38

A monoclonal antibody that specifically binds to CTLA-4 comprising a heavy chain amino acid sequence comprising SEQ ID NO: 70 and a light chain amino acid sequence comprising SEQ ID NO: 71.

### Claim 39

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4 comprising a heavy chain variable region amino acid sequence that utilizes a human VH3-33 family gene.

### Claim 40 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the antibody or antigen-binding portion thereof binds to a conformational epitope on human CTLA-4.

### Claim 41 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the antibody or antigen-binding portion thereof binds to human, cynomologous or marmoset CTLA-4 with about the same on-rate and off-rate.

### Claim 42 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the antibody or antigen-binding portion thereof inhibits human tumor growth.

### Claim 43 (depends on 6)

The monoclonal antibody or antigen-binding portion thereof of claim 6, wherein the monoclonal antibody or antigen-binding portion thereof binds to the same epitope on CTLA-4 as an antibody comprising a heavy chain amino acid sequence comprising amino acid residues 1-89 of SEQ ID NO: 9 and a light chain amino acid sequence comprising SEQ ID NO: 22.

### Claim 44 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4, wherein the monoclonal antibody or antigen-binding portion thereof competes for binding with CTLA-4 with an antibody comprising a heavy chain amino acid sequence comprising SEQ ID NO: 70 and a light chain amino acid sequence comprising SEQ ID NO: 71.

### Claim 45

An isolated human monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, wherein the monoclonal antibody or antigen-binding portion thereof has a binding affinity that is about 10−9 M, or greater affinity; possesses a selectivity for CTLA-4 over CD28, B7-2, CD44, and hIgG1 of greater than about 100:1; inhibits binding between CTLA-4 and B7-2 with an IC50 of lower than about 100 nM; and inhibits binding between CTLA-4 and B7-1 with an IC50 of lower than about 100 nM; and cross-competes for binding with CTLA-4 with an antibody comprising a heavy chain amino acid sequence comprising SEQ ID NO: 70 and a light chain amino acid sequence comprising SEQ ID NO: 71.

### Claim 46 (depends on 45)

The monoclonal antibody or antigen-binding portion thereof of claim 45, wherein the monoclonal antibody or antigen-binding portion thereof binds to the same epitope on CTLA-4 as an antibody comprising a heavy chain amino acid sequence comprising SEQ ID NO: 70 and a light chain amino acid sequence comprising SEQ ID NO: 71.

### Claim 47

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, comprising a heavy chain amino acid sequence comprising human FR1, FR2, and FR3 sequences that utilize a human VH 3-33 gene family operably linked in frame with a CDR1, a CDR2, and a CDR3 sequence, the CDR1 sequence being independently selected from amino acid residues 17-26 of SEQ ID NO: 72, 73, 74, 75, 76, 80, 81 or 83, amino acid residues 13-22 of SEQ ID NO: 77 or 78, amino acid residues 18-27 of SEQ ID NO: 79, amino acid residues 16-25 of SEQ ID NO: 82, or amino acid residues 15-24 of SEQ ID NO; 84; the CDR2 sequence being independently selected from amino acid residues 41-55 of SEQ ID NO: 72, 73, 74, 75, 76, 80, 81 or 83, amino acid residues 37-51 of SEQ. ID NO: 77 or 78, amino acid residues 42-56 of SEQ ID NO: 79, amino acid residues 40-54 of SEQ ID NO: 82, or amino acid residues 39-53 of SEQ ID NO: 84; and the CDR3 sequence being independently selected from amino acid residues 90-100 of SEQ ID NO: 73 or 81, amino acid residues 90-98 of SEQ ID NO: 74 or 76, amino acid residues 90-99 of SEQ ID NO: 75, amino acid residues 86-94 of SEQ ID NO: 77 or 78, amino acid residues 91-99 of SEQ ID NO: 79, amino acid residues 90-105 of SEQ ID NO: 80, amino acid residues 89-99 of SEQ ID NO: 82, amino acid residues 90-104 of SEQ ID NO: 83, or amino acid residues 88-99 of SEQ ID NO: 84.

### Claim 48

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4, comprising a heavy chain amino acid sequence comprising FR1, FR2, and FR3 sequences operably linked in frame with a CDR1, a CDR2, and a CDR3 sequence, the CDR1 sequence being independently selected from amino acid residues 17-26 of SEQ ID NO: 72, 73, 74, 75, 76, 80, 81 or 83, amino acid residues 13-22 of SEQ ID NO: 77 or 78, amino acid residues 18-27 of SEQ ID NO: 79, amino acid residues 16-25 of SEQ ID NO: 82, amino acid residues 15-24 of SEQ ID NO: 84, or amino acid residues 24-31 of SEQ ID NO: 86; the CDR2 sequence being independently selected from amino acid residues 41-55 of SEQ ID NO: 72, 73, 74, 75, 76, 80, 81 or 83, amino acid residues 37-51 of SEQ ID NO: 77 or 78, amino acid residues 42-56 of SEQ ID NO: 79, amino acid residues 40-54 of SEQ ID NO: 82, amino acid residues 39-53 of SEQ ID NO: 84, or amino acid residues 44-61 of SEQ ID NO: 86; and the CDR3 sequence being independently selected from amino acid residues 90-100 of SEQ ID NO: 73 or 81, amino acid residues 90-98 of SEQ ID NO: 74 or 76, amino acid residues 90-99 of SEQ ID NO: 75, amino acid residues 86-94 of SEQ ID NO: 77 or 78, amino acid residues 91-99 of SEQ ID NO: 79, amino acid residues 90-105 of SEQ ID NO: 80, amino acid residues 89-99 of SEQ ID NO: 82, amino acid residues 90-104 of SEQ ID NO: 83, amino acid residues 88-99 of SEQ ID NO: 84, or amino acid residues 94-102 of SEQ ID NO: 86,
which antibody or antigen-binding portion thereof has the following properties:
a binding affinity for CTLA-4 that is about 10−9 M, or greater affinity;
inhibits binding between CTLA-4 and B7-1 with an IC50 of about 100 nM or lower;
inhibits binding between CTLA-4 and B7-2 with an IC50 of about 100 nM or lower; and
enhances cytokine production in a human T cell blast/Raji assay by 500 pg/ml or greater.

### Claim 49

A monoclonal antibody or antigen-binding portion thereof that specifically binds to CTLA-4 comprising a light chain variable region amino acid sequence that comprises the variable region amino acid sequence in SEQ ID NO: 71.

### Claim 50 (depends on 1)

The monoclonal antibody or antigen-binding portion thereof of claim 1 that is a monoclonal antibody.

### Claim 51 (depends on 2)

The monoclonal antibody or antigen-binding portion thereof of claim 2 that is a monoclonal antibody.

### Claim 52 (depends on 3)

The monoclonal antibody or antigen-binding portion thereof of claim 3 that is a monoclonal antibody.

### Claim 53 (depends on 4)

The monoclonal antibody or antigen-binding portion thereof of claim 4 that is a monoclonal antibody.

### Claim 54 (depends on 5)

The monoclonal antibody or antigen-binding portion thereof of claim 5 that is a monoclonal antibody.

### Claim 55 (depends on 6)

The monoclonal antibody or antigen-binding portion thereof of claim 6 that is a monoclonal antibody.

### Claim 56 (depends on 7)

The monoclonal antibody or antigen-binding portion thereof of claim 7 that is a monoclonal antibody.

### Claim 57 (depends on 8)

The monoclonal antibody or antigen-binding portion thereof of claim 8 that is a monoclonal antibody.

### Claim 58 (depends on 9)

The monoclonal antibody or antigen-binding portion thereof of claim 9 that is a monoclonal antibody.

### Claim 59 (depends on 10)

The monoclonal antibody or antigen-binding portion thereof of claim 10 that is a monoclonal antibody.

### Claim 60 (depends on 11)

The monoclonal antibody or antigen-binding portion thereof of claim 11 that is a monoclonal antibody.

### Claim 61 (depends on 12)

The monoclonal antibody or antigen-binding portion thereof of claim 12 that is a monoclonal antibody.

### Claim 62 (depends on 13)

The monoclonal antibody or antigen-binding portion thereof of claim 13 that is a monoclonal antibody.

### Claim 63 (depends on 14)

The monoclonal antibody or antigen-binding portion thereof of claim 14 that is a monoclonal antibody.

### Claim 64 (depends on 15)

The monoclonal antibody or antigen-binding portion thereof of claim 15 that is a monoclonal antibody.

### Claim 65 (depends on 16)

The monoclonal antibody or antigen-binding portion thereof of claim 16 that is a monoclonal antibody.

### Claim 66 (depends on 17)

The monoclonal antibody or antigen-binding portion thereof of claim 17 that is a monoclonal antibody.

### Claim 67 (depends on 18)

The monoclonal antibody or antigen-binding portion thereof of claim 18 that is a monoclonal antibody.

### Claim 68 (depends on 19)

The monoclonal antibody or antigen-binding portion thereof of claim 19 that is a monoclonal antibody.

### Claim 69 (depends on 20)

The monoclonal antibody or antigen-binding portion thereof of claim 20 that is a monoclonal antibody.

### Claim 70 (depends on 21)

The monoclonal antibody or antigen-binding portion thereof of claim 21 that is a monoclonal antibody.

### Claim 71 (depends on 22)

The monoclonal antibody or antigen-binding portion thereof of claim 22 that is a monoclonal antibody.

### Claim 72 (depends on 23)

The monoclonal antibody or antigen-binding portion thereof of claim 23 that is a monoclonal antibody.

### Claim 73 (depends on 24)

The monoclonal antibody or antigen-binding portion thereof of claim 24 that is a monoclonal antibody.

### Claim 74 (depends on 25)

The monoclonal antibody or antigen-binding portion thereof of claim 25 that is a monoclonal antibody.

### Claim 75 (depends on 26)

The monoclonal antibody or antigen-binding portion thereof of claim 26 that is a monoclonal antibody.

### Claim 76 (depends on 27)

The monoclonal antibody or antigen-binding portion thereof of claim 27 that is a monoclonal antibody.

### Claim 77 (depends on 28)

The monoclonal antibody or antigen-binding portion thereof of claim 28 that is a monoclonal antibody.

### Claim 78 (depends on 29)

The monoclonal antibody or antigen-binding portion thereof of claim 29 that is a monoclonal antibody.

### Claim 79 (depends on 30)

The monoclonal antibody or antigen-binding portion thereof of claim 30 that is a monoclonal antibody.

### Claim 80 (depends on 31)

The monoclonal antibody or antigen-binding portion thereof of claim 31 that is a monoclonal antibody.

### Claim 81 (depends on 32)

The monoclonal antibody or antigen-binding portion thereof of claim 32 that is a monoclonal antibody.

### Claim 82 (depends on 33)

The monoclonal antibody or antigen-binding portion thereof of claim 33 that is a monoclonal antibody.

### Claim 83 (depends on 34)

The monoclonal antibody or antigen-binding portion thereof of claim 34 that is a monoclonal antibody.

### Claim 84 (depends on 35)

The monoclonal antibody or antigen-binding portion thereof of claim 35 that is a monoclonal antibody.

### Claim 85 (depends on 36)

The monoclonal antibody or antigen-binding portion thereof of claim 36 that is a monoclonal antibody.

### Claim 86 (depends on 37)

The monoclonal antibody or antigen-binding portion thereof of claim 37 that is a monoclonal antibody.

### Claim 87 (depends on 38)

The monoclonal antibody or antigen-binding portion thereof of claim 38 that is a monoclonal antibody.

### Claim 88 (depends on 39)

The monoclonal antibody or antigen-binding portion thereof of claim 39 that is a monoclonal antibody.

### Claim 89 (depends on 40)

The monoclonal antibody or antigen-binding portion thereof of claim 40 that is a monoclonal antibody.

### Claim 90 (depends on 41)

The monoclonal antibody or antigen-binding portion thereof of claim 41 that is a monoclonal antibody.

### Claim 91 (depends on 42)

The monoclonal antibody or antigen-binding portion thereof of claim 42 that is a monoclonal antibody.

### Claim 92 (depends on 43)

The monoclonal antibody or antigen-binding portion thereof of claim 43 that is a monoclonal antibody.

### Claim 93 (depends on 44)

The monoclonal antibody or antigen-binding portion thereof of claim 44 that is a monoclonal antibody.

### Claim 94 (depends on 45)

The monoclonal antibody or antigen-binding portion thereof of claim 45 that is a monoclonal antibody.

### Claim 95 (depends on 46)

The monoclonal antibody or antigen-binding portion thereof of claim 46 that is a monoclonal antibody.

### Claim 96 (depends on 47)

The monoclonal antibody or antigen-binding portion thereof of claim 47 that is a monoclonal antibody.

### Claim 97 (depends on 48)

The monoclonal antibody or antigen-binding portion thereof of claim 48 that is a monoclonal antibody.

### Claim 98 (depends on 49)

The monoclonal antibody or antigen-binding portion thereof of claim 49 is a monoclonal antibody.

### Claim 99 (depends on 38)

The monoclonal antibody of claim 38 that has a heavy chain amino acid sequence of SEQ ID NO: 70 and a light chain amino acid sequence of SEQ ID NO: 71.

### Claim 100 (depends on 4)

A composition comprising the monoclonal antibody or antigen-binding portion of claim 4 and a pharmaceutically acceptable carrier.

### Claim 101 (depends on 38)

A composition comprising the monoclonal antibody of claim 38 and a pharmaceutically acceptable carrier.

### Claim 102

A monoclonal antibody or antigen binding portion thereof that specifically binds to CTLA-4, wherein the heavy chain variable region and the light chain variable region are produced by hybridoma cell line 11.2.1.4 deposited under ATCC Accession No. PTA-5169.

### Claim 103 (depends on 102)

The monoclonal antibody or antigen-binding portion thereof of claim 102 that is a monoclonal antibody.

### Claim 104

A monoclonal antibody that specifically binds to CTLA-4 and is produced by hybridoma cell line 11.2.1.4 deposited under ATCC Accession No. PTA-5169.
